04
Nov
2009
Pulmatrix | Series B $30.2 M
Posted in MA Private: Pulmatrix, Series B, X - Influenza, X - Respiratory
Based in Lexington, MA Pulmatrix is a clinical-stage pharmaceutical company developing a broad new class of inhaled therapies for the treatment and prevention of infectious and progressive respiratory diseases via a fundamentally new way approach through potentially simple and safe therapies that harness the airway and lungs own natural biophysical properties and host defense mechanisms.
Rather [...]
06
Oct
2009
Biodesix (Broomfiled, CO) a commercial-stage molecular diagnostics company focused on proteomic-based diagnostics, closed the first tranche of a $10M Series B financing. The company is enabling personalized health care via their mass spectrometry-based molecular profiling proprietary platform technology, ProTS®, to discover and validate diagnostic tests for the improvement of patient outcomes.
Biodesix’ first product, VeriStrat®, a [...]
01
Feb
2008
Taligen Therapeutics announced the close of a $65M Series B financing led by Alta Partners and Clarus Ventures and with ongoing participation from existing partners Sanderling Ventures, Tango and High Country Venture.
All I can say is ‘WOW’! I would be willing to bet a dollar that there is not a larger Series B financing [...]
13
Jun
2007
ARCA Discovery, Inc. closed an $18M Series B led by Skyline Ventures and additional new investor InterWest Partners, previous investors Atlas Ventures, Boulder Ventures and the Peierls Foundation also participated in the round.
ARCA is aiming for an NDA submission in 2007 for Bucindolol, a next-generation beta-blocker and vasodilator for heart failure, and plans to seek [...]
18
Oct
2006
Efficas: $14.5M Series B
Posted in Series B
Efficas, Inc., a biotech health, wellness and medical foods company focused on nutritional management of the immune system, has raised $14.5M in Series B funding. LSP BioVentures led the deal, and was joined by Unilever Technology Ventures and included return backers Burrill & Co., Great Spirit Ventures, JPMorgan Bay Area Equity Fund and Prolog Ventures. [...]
18
Aug
2006
Accera, Inc. Closes $7.5M Series B
Posted in Series B
Broomfield, CO based Accera, Inc., a drug development company focused on Alzheimer’s disease and related neurodegenerative diseases, announced it has recently closed a Series B financing of $7.5M led by returning investors Inventages Venture Capital, POSCO BioVentures and several unnamed private investors. In 2004 Accera closed their $6M Series A round.
Based upon their Neuron [...]
20
Jan
2006
CardioOptics, Inc., a medical device company developing and commercializing unique therapeutic catheter systems that allow doctors to see directly through flowing blood and inside the heart as they treat cardiovascular disease, has completed a $26.5 million Series B financing. The round was led by new investor Novo A/S and joined by Investor Growth Capital, Inc., [...]
Life Science Deal Flow PARTNERS
-
